Loading...

We've got a brand new version of Simply Wall St! Try it out

Body and Mind

CNSX:BAMM
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BAMM
CNSX
CA$104M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Body and Mind Inc., a development stage company, produces medical and recreational marijuana. The last earnings update was 93 days ago. More info.


Add to Portfolio Compare Print
  • Body and Mind has significant price volatility in the past 3 months.
BAMM Share Price and Events
7 Day Returns
-6.3%
CNSX:BAMM
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
170.7%
CNSX:BAMM
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
BAMM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Body and Mind (BAMM) -6.3% 59.5% -2.2% 170.7% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • BAMM outperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • BAMM outperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
BAMM
Industry
5yr Volatility vs Market

Value

 Is Body and Mind undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Body and Mind. This is due to cash flow or dividend data being unavailable. The share price is CA$1.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Body and Mind's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Body and Mind's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BAMM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $-0.04
CNSX:BAMM Share Price ** CNSX (2019-09-19) in CAD CA$1.34
CNSX:BAMM Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $1.01
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Body and Mind.

CNSX:BAMM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BAMM Share Price ÷ EPS (both in USD)

= 1.01 ÷ -0.04

-28.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Body and Mind is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Body and Mind is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Body and Mind's expected growth come at a high price?
Raw Data
CNSX:BAMM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -28.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Body and Mind, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Body and Mind's assets?
Raw Data
CNSX:BAMM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $0.26
CNSX:BAMM Share Price * CNSX (2019-09-19) in CAD CA$1.34
CNSX:BAMM Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $1.01
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:BAMM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BAMM Share Price ÷ Book Value per Share (both in USD)

= 1.01 ÷ 0.26

3.93x

* Primary Listing of Body and Mind.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Body and Mind is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Body and Mind's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Body and Mind has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Body and Mind expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Body and Mind has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Body and Mind expected to grow at an attractive rate?
  • Unable to compare Body and Mind's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Body and Mind's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Body and Mind's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:BAMM Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BAMM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BAMM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 4 -2 -2
2019-01-31 4 -2 -2
2018-10-31 4 -2 -2
2018-07-31 2 -2 -2
2018-04-30 1 -1 -2
2018-01-31 1 -2 -2
2017-10-31 -1 -1
2017-07-31 0 0
2017-04-30 0 0
2017-01-31 0 0
2016-10-31 0 0
2016-07-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Body and Mind is high growth as no earnings estimate data is available.
  • Unable to determine if Body and Mind is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BAMM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Body and Mind Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BAMM Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 -0.04
2019-01-31 -0.04
2018-10-31 -0.03
2018-07-31 -0.05
2018-04-30 -0.06
2018-01-31 -0.08
2017-10-31 -0.07
2017-07-31 -0.06
2017-04-30 0.19
2017-01-31 0.22
2016-10-31 0.22
2016-07-31 0.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Body and Mind will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Body and Mind's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Body and Mind's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Body and Mind's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Body and Mind's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Body and Mind has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Body and Mind performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Body and Mind's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Body and Mind does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Body and Mind's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Body and Mind's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Body and Mind's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Body and Mind Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BAMM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 4.23 -2.10 3.22
2019-01-31 3.86 -2.34 3.24
2018-10-31 3.61 -1.54 2.43
2018-07-31 2.41 -1.78 2.34
2018-04-30 1.48 -1.93 1.79
2018-01-31 0.83 -1.68 1.72
2017-10-31 -0.74 0.70
2017-07-31 -0.37 0.34
2017-04-30 0.47 0.16
2017-01-31 0.48 0.11
2016-10-31 0.47 0.10
2016-07-31 0.46 0.12
2016-04-30 -0.23 0.12
2016-01-31 -0.24 0.12
2015-10-31 -0.26 0.13
2015-07-31 -0.27 0.13
2015-04-30 -0.18 0.12
2015-01-31 -0.20 0.13
2014-10-31 -0.30 0.24
2014-07-31 -0.27 0.27
2014-04-30 -0.41 0.28
2014-01-31 -0.46 0.33
2013-10-31 -0.39 0.26
2013-07-31 -0.43 0.31
2013-04-30 -1.06 0.66
2013-01-31 -1.13 0.74
2012-10-31 -1.21 0.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Body and Mind has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Body and Mind has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Body and Mind improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Body and Mind's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Body and Mind has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Body and Mind's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Body and Mind's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Body and Mind's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Body and Mind's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Body and Mind's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Body and Mind Company Filings, last reported 4 months ago.

CNSX:BAMM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 18.68 5.79 2.59
2019-01-31 17.83 5.50 2.72
2018-10-31 10.65 2.18 0.10
2018-07-31 10.79 2.18 0.32
2018-04-30 14.42 1.95 1.05
2018-01-31 14.81 2.18 1.68
2017-10-31 4.57 0.00 4.68
2017-07-31 0.32 0.00 0.37
2017-04-30 0.50 0.00 0.69
2017-01-31 -0.39 0.09 0.00
2016-10-31 -0.35 0.07 0.00
2016-07-31 -0.35 0.08 0.00
2016-04-30 -1.01 0.08 0.00
2016-01-31 -0.88 0.07 0.00
2015-10-31 -0.91 0.07 0.00
2015-07-31 -0.88 0.07 0.00
2015-04-30 -0.86 0.07 0.00
2015-01-31 -0.80 0.07 0.00
2014-10-31 -0.83 0.08 0.00
2014-07-31 -0.82 0.08 0.00
2014-04-30 -0.70 0.08 0.00
2014-01-31 -0.64 0.07 0.00
2013-10-31 -0.61 0.09 0.02
2013-07-31 -0.60 0.09 0.00
2013-04-30 -0.47 0.09 0.00
2013-01-31 -0.38 0.09 0.00
2012-10-31 -0.29 0.08 0.00
  • Body and Mind's level of debt (31%) compared to net worth is satisfactory (less than 40%).
  • Body and Mind had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Body and Mind has sufficient cash runway for 1.3 years based on current free cash flow.
  • Body and Mind has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 87.6% each year.
X
Financial health checks
We assess Body and Mind's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Body and Mind has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Body and Mind's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Body and Mind dividends.
If you bought CA$2,000 of Body and Mind shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Body and Mind's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Body and Mind's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BAMM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Body and Mind has not reported any payouts.
  • Unable to verify if Body and Mind's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Body and Mind's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Body and Mind has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Body and Mind's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Body and Mind afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Body and Mind has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Body and Mind's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Mills
TENURE AS CEO 0.1 years
CEO Bio

Mr. Michael Mills, also known as Mike, has been President & Interim CEO at Body and Mind, Inc. since August 2019 and served as its Vice President of Communications since June 2018 until August 2019. Mr. Mills brings a breadth of experience which most recently includes a long-term engagement with a TSX Venture Exchange listed company and a previous career with the Financial Post and National Post newspapers.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Body and Mind management team in years:

0.1
Average Tenure
44
Average Age
  • The average tenure for the Body and Mind management team is less than 2 years, this suggests a new team.
Management Team

Dong Shim

TITLE
CFO & Director
COMPENSATION
$98K
AGE
35
TENURE
0.1 yrs

Darren Tindale

TITLE
Corporate Secretary
COMPENSATION
$108K
AGE
46
TENURE
0.1 yrs

Mike Mills

TITLE
President & Interim CEO
TENURE
0.1 yrs

Trip Hoffman

TITLE
Chief Operating Officer
TENURE
0.8 yrs

Bobby Grewal

TITLE
Vice President of Corporate Development
AGE
44
TENURE
8.5 yrs
Board of Directors Tenure

Average tenure and age of the Body and Mind board of directors in years:

5
Average Tenure
51
Average Age
  • The tenure for the Body and Mind board of directors is about average.
Board of Directors

Tookie Angus

TITLE
Member of Advisory Board
AGE
70
TENURE
7.3 yrs

Dong Shim

TITLE
CFO & Director
COMPENSATION
$98K
AGE
35
TENURE
2.8 yrs

Robert Green

TITLE
Member of Advisory Board
TENURE
7.3 yrs

Michael Lee

TITLE
Member of Advisory Board
TENURE
7.3 yrs

Vitorio Stana

TITLE
Member of Advisory Board
TENURE
7.3 yrs

Alec Rossa

TITLE
Member of Advisory Board

Robert Hasman

TITLE
Director
AGE
37
TENURE
1.8 yrs

Kevin Hooks

TITLE
Director
AGE
57
TENURE
1.8 yrs

Scott Dowty

TITLE
Director
AGE
51
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
06. Feb 19 Buy Australis Capital Inc. Company 01. Feb 19 01. Feb 19 1,768,545 CA$0.58 CA$1,018,549
X
Management checks
We assess Body and Mind's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Body and Mind has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Body and Mind Inc., a development stage company, produces medical and recreational marijuana. The company offers packaged and grinded flower buds; BHO shatter glass concentrates and BHO sugar/salt concentrates; disposable pen vaporizers; distillate oil cartridges; rosin, a heat compressed concentrate; and distillate infused edible products, including gummies, hard candies, beef jerky, dried fruits, and pretzel bites. It produces and sells flowers, oil extracts, and edibles through licensed dispensaries in Nevada. The company was formerly known as Deploy Technologies Inc. and changed its name to Body and Mind Inc. in November 2017. Body and Mind Inc. was founded in 1998 and is headquartered in Vancouver, Canada.

Details
Name: Body and Mind Inc.
BAMM
Exchange: CNSX
Founded: 1998
CA$103,732,564
101,698,593
Website: http://www.bamcannabis.com
Address: Body and Mind Inc.
750 – 1095 West Pender Street,
Vancouver,
British Columbia, V6E 2M6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BAMM Common Stock Canadian National Stock Exchange CA CAD 06. Nov 2005
Number of employees
Current staff
Staff numbers
32
Body and Mind employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:05
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/06/19
Last earnings reported: 2019/04/30
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.